A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia
Revumenib/SNDX-5613 is an investigational, novel, orally available Menin-MLL1 inhibitor.2 The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mutation.4,5
Prevalence6
- MLL rearrangements are found in 5% to 10% of adult AML and B-ALL cases and >70% of infant leukemias
- NPM1 mutations are found in about 25% to 30% of all adult AML
AUGMENT-102/NCT05326516: A Phase 1, Open-Label, Dose-escalation study to Evlaulate Safety, Tolerability, and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy3 in Patients with Relapsed/Refractory Leukemias harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1).1
This trial is actively recruiting